Hepatect Cp

Hepatect Cp is a prescription injectable solution containing Human Hepatitis B Immunoglobulin as the active ingredient. It is supplied as an intravenous infusion product without a specified strength, used to provide passive immunity against hepatitis B virus. The preparation is marketed in the European Union and belongs to the immunoglobulin drug class with antiviral therapeutic activity.

Hepatect Cp is indicated for several clinical situations where passive immunity against hepatitis B virus is required.

- Post‑exposure prophylaxis after known or suspected exposure to hepatitis B virus. - Prevention of hepatitis B virus recurrence in patients undergoing liver transplantation. - Prophylaxis of newborns born to hepatitis B‑positive mothers when administered with hepatitis B vaccine. - Protection of healthcare workers after occupational exposure to hepatitis B infected blood or body fluids. - Supplementary protection for individuals with inadequate response to hepatitis B vaccination.

Side effects of Hepatect Cp are generally related to the infusion process and immune response.

Common: - Mild fever or chills during or shortly after infusion. - Headache or fatigue. - Localized pain or erythema at the infusion site. - Nausea or mild gastrointestinal discomfort. - Transient elevations in liver enzymes.

Serious: - Severe allergic reactions, including anaphylaxis. - Acute hemolysis. - Renal impairment or acute kidney injury. - Thromboembolic events. - Severe hypotension or cardiovascular collapse. - Disseminated intravascular coagulation (DIC).

When prescribing Hepatect Cp, clinicians should consider several safety factors.

- Assess patient history for prior hypersensitivity to human immunoglobulins or blood products. - Monitor vital signs and for signs of allergic reaction during the first infusion. - Use caution in patients with renal insufficiency or a history of thromboembolic disease. - Evaluate liver function tests before and during therapy, especially in transplant recipients. - Avoid use in individuals with uncontrolled hypertension or active bleeding disorders. - Pregnancy and lactation status should be reviewed, as safety data are limited.

Hepatect Cp may interact with other medications or clinical conditions.

Avoid: - Concurrent administration of other blood‑derived products without appropriate monitoring. - Use with known anaphylactogenic agents in patients with a history of severe allergic reactions.

Use with caution: - Immunosuppressive agents, as they may alter the efficacy of passive immunity. - Anticoagulants, due to potential increased risk of bleeding at the infusion site. - Nephrotoxic drugs, because of added renal stress. - Vaccines other than hepatitis B vaccine, to avoid interference with immune response. - High‑dose corticosteroids, which may mask infusion‑related reactions.